NCT01122680 - Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma | Biotech Hunter

Enrollment

105

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

April 30, 2011

Conditions

Asthma

Interventions

DRUG

Tiotropium bromide

inhalation solution, dose of 1.25 mcg (2 puffs of 0.625 mcg)

DRUG

tiotropium bromide

inhalation solution, dose of 2.5 mcg (2 puffs of 1.25 mcg)

DRUG

tiotropium bromide

inhalation solution, dose of 5 mcg (2 puffs of 2.5 mcg)

DRUG

Placebo

placebo inhalation solution

Trial Locations (19)

205.424.01002 Boehringer Ingelheim Investigational Site, Denver

205.424.01006 Boehringer Ingelheim Investigational Site, Columbia

205.424.01007 Boehringer Ingelheim Investigational Site, Warrensburg

205.424.01004 Boehringer Ingelheim Investigational Site, Boys Town

205.424.01001 Boehringer Ingelheim Investigational Site, Canton

205.424.49007 Boehringer Ingelheim Investigational Site, Koblenz

205.424.49004 Boehringer Ingelheim Investigational Site, Rosenheim

205.424.49002 Boehringer Ingelheim Investigational Site, Wesel

205.424.37104 Boehringer Ingelheim Investigational Site, Balvi

205.424.37103 Boehringer Ingelheim Investigational Site, Daugavpils

205.424.37105 Boehringer Ingelheim Investigational Site, Rēzekne

205.424.37101 Boehringer Ingelheim Investigational Site, Riga

205.424.37102 Boehringer Ingelheim Investigational Site, Riga

205.424.37001 Boehringer Ingelheim Investigational Site, Vilnius

205.424.37003 Boehringer Ingelheim Investigational Site, Vilnius

205.424.37004 Boehringer Ingelheim Investigational Site, Vilnius

205.424.38604 Boehringer Ingelheim Investigational Site, Kamnik

205.424.38605 Boehringer Ingelheim Investigational Site, Ljubljana

205.424.38602 Boehringer Ingelheim Investigational Site, Maribor